Form 144 BioNTech SE Filed by: Tureci Ozlem
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
BioNTech (BNTX) PT Raised to $121 at Leerink Partners
November 13, 2024 7:26 AM ESTLeerink Partners analyst Daina Graybosch raised the price target on BioNTech (NASDAQ: BNTX) to $121.00 (from $102.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: BioNTech (BNTX, OP) seeks to drive top-line growth through excellence in oncology drug development, and tomorrow's Innovation Series (11/14) event is poised to be an important... More
